DaVita (DVA) Stock Buyback History
TTM buyback yield 15.91% · Shareholder yield (TTM) 15.91%.
DVA
TTM buyback yield
15.91%
Shareholder yield (TTM)
15.91%
5Y share count change
-28.2%
TTM buyback spend
$1.65B
SBC coverage (TTM)
16.48x
YoY change in spend
+29.4%
5Y CAGR of spend
+4.2%
Peak year (2019)
$2.38B
Cumulative spend
$15.53B
TTM metrics calculated from the four most recent reported quarters, ending (reported ).
Key takeaways
- DaVita (DVA) repurchased about $1.65B of stock over the trailing twelve months.
- Diluted share count is down 28.2% over the last ~5 fiscal years — buybacks are net-shrinking the share base.
- TTM buyback ÷ stock-based-comp ratio of 16.48× — repurchases more than cover SBC dilution.
- Cash buyback spend has compounded at +4.2% per year over the latest 5-year window.
- TTM repurchases used about 110% of free cash flow remaining after dividends.
Buyback context per fiscal year
Annual repurchases alongside stock-based compensation, diluted share count and the year-over-year change — useful for SBC-coverage and dilution-offset reading at a glance.
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $1.79B | $139.95M | $1.65B | 0.09B | 0.9% | 18.33% |
| 2024 | $1.39B | $102.79M | $1.28B | 0.09B | -6.3% | 11.35% |
| 2023 | $272.22M | $112.38M | $159.84M | 0.09B | -2.8% | 2.88% |
| 2022 | $802.23M | $95.43M | $706.80M | 0.10B | -12.8% | 11.92% |
| 2021 | $1.60B | $102.21M | $1.50B | 0.11B | -10.3% | 13.93% |
| 2020 | $1.46B | $91.46M | $1.37B | 0.12B | -20.3% | 11.13% |
| 2019 | $2.38B | $67.85M | $2.32B | 0.15B | -10.8% | 24.54% |
| 2018 | $1.16B | $73.06M | $1.09B | 0.17B | -9.9% | 13.60% |
| 2017 | $802.95M | $35.09M | $767.86M | 0.19B | -6.6% | 6.10% |
| 2016 | $1.10B | $38.34M | $1.06B | 0.20B | -5.2% | 8.81% |
| 2015 | $549.93M | $56.66M | $493.27M | 0.22B | -0.3% | 3.78% |
| 2014 | $0.00 | $54.97M | −$54.97M | 0.22B | 1.0% | — |
| 2013 | $0.00 | $60.00M | −$60.00M | 0.21B | 9.6% | — |
| 2012 | $0.00 | $45.38M | −$45.38M | 0.20B | 1.5% | — |
| 2011 | $323.35M | $48.72M | $274.63M | 0.19B | -6.3% | 4.56% |
| 2010 | $618.50M | $45.55M | $572.95M | 0.21B | -1.1% | 9.25% |
| 2009 | $153.50M | $44.42M | $109.07M | 0.21B | -1.7% | 2.54% |
| 2008 | $257.12M | $41.23M | $215.89M | 0.21B | -1.4% | 4.99% |
| 2007 | $6.35M | $34.15M | −$27.80M | 0.21B | 1.5% | 0.11% |
| 2006 | $0.00 | $26.39M | −$26.39M | 0.21B | 1.7% | — |
| 2005 | $0.00 | $21.66M | −$21.66M | 0.21B | 1.2% | — |
| 2004 | $96.54M | $5.82M | $90.72M | 0.21B | -9.6% | 2.49% |
| 2003 | $107.16M | $5.82M | $101.34M | 0.23B | -16.2% | 4.28% |
| 2002 | $642.17M | $6.84M | $635.33M | 0.27B | -2.6% | 43.40% |
| 2001 | $20.36M | $17.99M | $2.37M | 0.28B | 11.8% | 1.00% |
| 2000 | $0.00 | $0.00 | $0.00 | 0.25B | 2.5% | — |
| 1999 | $0.00 | $0.00 | $0.00 | 0.24B | -0.7% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.25B | 17.6% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.21B | 0.0% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.21B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
Cash buyback spend (USD) — annual & quarterly history
Trailing-twelve-month and per-period cash repurchases for DaVita (DVA) from the consolidated cash flow statement (line: common stock repurchased), in USD as filed.
Cash buyback spend over time for DaVita (DVA)
Per-period cash repurchases
Cash buyback spend annual + quarterly history for DaVita (DVA)
| Fiscal year | Period ended | Reported | Buyback Spend | YoY | YoY change |
|---|---|---|---|---|---|
| 2025 | $1.79B | +29.4% | +$407.07M | ||
| 2024 | $1.39B | +409.1% | +$1.11B | ||
| 2023 | $272.22M | -66.1% | -$530.01M | ||
| 2022 | $802.23M | -49.8% | -$796.40M | ||
| 2021 | $1.60B | +9.5% | +$139.21M | ||
| 2020 | $1.46B | -38.8% | -$924.40M | ||
| 2019 | $2.38B | +105.2% | +$1.22B | ||
| 2018 | $1.16B | +44.7% | +$358.56M | ||
| 2017 | $802.95M | -26.9% | -$294.87M | ||
| 2016 | $1.10B | +99.6% | +$547.89M | ||
| 2015 | $549.93M | — | +$549.93M | ||
| 2014 | $0 | — | $0 | ||
| 2013 | $0 | — | $0 | ||
| 2012 | $0 | -100.0% | -$323.35M | ||
| 2011 | $323.35M | -47.7% | -$295.15M | ||
| 2010 | $618.50M | +302.9% | +$465.00M | ||
| 2009 | $153.50M | -40.3% | -$103.63M | ||
| 2008 | $257.12M | +3949.2% | +$250.77M | ||
| 2007 | $6.35M | — | +$6.35M | ||
| 2006 | $0 | — | $0 | ||
| 2005 | $0 | -100.0% | -$96.54M | ||
| 2004 | $96.54M | -9.9% | -$10.62M | ||
| 2003 | $107.16M | -83.3% | -$535.01M | ||
| 2002 | $642.17M | +3054.1% | +$621.81M | ||
| 2001 | $20.36M | — | +$20.36M | ||
| 2000 | $0 | — | $0 | ||
| 1999 | $0 | — | $0 | ||
| 1998 | $0 | — | $0 | ||
| 1997 | $0 | — | $0 | ||
| 1996 | $0 | — | $0 | ||
| 1995 | $0 | — | $0 | ||
| 1994 | $0 | — | — |
As of the 2025 fiscal year, DaVita (DVA) reported buyback spend of $1.79B – grew 29.4% year-over-year.
DaVita buyback spend has grown for 2 consecutive years, with a +4.2% compound annual growth rate over 2020–2025 (5 years).
DaVita buyback spend peaked at $2.38B in 2019; the latest annual figure is $1.79B in 2025 (24.8% below peak).
The highest annual buyback spend of $2.38B was reported in 2019. The lowest in the available history was $0 in 1994.
Within Healthcare, DaVita (DVA) ranks 5th among 8 peers we track. The peer median for buyback spend is $2.75B.
DaVita Buyback Spend 2025: $1.79B
DaVita buyback spend in 2025 was $1.79B, grew 29.4% from 2024.
DaVita Buyback Spend 2024: $1.39B
DaVita buyback spend in 2024 was $1.39B, surged 409.1% from 2023.
DaVita Buyback Spend 2023: $272.22M
DaVita buyback spend in 2023 was $272.22M, plunged 66.1% below 2022.
DaVita Buyback Spend 2022: $802.23M
DaVita buyback spend in 2022 was $802.23M, plunged 49.8% below 2021.
DaVita Buyback Spend 2021: $1.60B
DaVita buyback spend in 2021 was $1.60B.
See more financial history for DaVita (DVA).
Sector peers by buyback spend
Companies in the same sector as DaVita, ranked by their latest buyback spend.
| Company | Buyback Spend | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $5.95B | Healthcare |
| UnitedHealth Group (UNH) | $5.54B | Healthcare |
| Merck & Co. (MRK) | $5.08B | Healthcare |
| Eli Lilly (LLY) | $4.11B | Healthcare |
| Novo Nordisk (NVO) | $1.39B | Healthcare |
| AbbVie (ABBV) | $980.00M | Healthcare |
| AstraZeneca (AZN) | $719.66M | Healthcare |
| Amgen (AMGN) | $0 | Healthcare |
Share count history
Diluted weighted-average shares drive the EPS denominator and per-share capital-return maths. A falling diluted share count means buybacks are outpacing dilution from stock-based compensation and option exercises.
Diluted vs basic shares (annual)
Year-over-year change in diluted shares
Green is fewer shares vs the prior fiscal year (net repurchase); red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield over time
Stacked annual yields — buyback yield (TTM cash repurchases ÷ market cap) plus dividend yield from the same fiscal-year-end key-metrics period — show how total cash return per dollar of equity has evolved.
Buybacks vs stock-based compensation
Annual cash repurchases set against stock-based compensation. Coverage above 1× means buybacks fully offset the equity dilution from SBC. TTM coverage: 16.48×.
Capital allocation mix
How DaVita splits cash returned to shareholders between dividends and buybacks, plus the headroom on free cash flow that's still available for additional repurchases.
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
Free cash flow minus dividends paid versus actual TTM repurchases — the headroom bar shows how much of post-dividend FCF is still being deployed elsewhere.
Headroom $1.49B (TTM FCF − TTM dividends, clamped at zero).
Data & methodology
Where do buyback, dividend and compensation figures come from?
Cash buyback spend (common stock repurchased), dividends paid and stock-based compensation come from DaVita's consolidated cash flow statements — quarterly 10-Q and annual 10-K SEC filings, in USD as reported.
How are diluted shares and yields calculated?
Diluted weighted-average share counts come from the income statement (EPS denominator). Trailing twelve-month (TTM) aggregates sum the four most recent reported quarters. Buyback and dividend yields divide TTM cash flows by market capitalisation at the latest quarter-end.
How is buyback capacity defined?
Capacity compares TTM repurchases to free cash flow after dividends: operating cash flow minus capital expenditure, minus dividends paid, versus actual buybacks over the same trailing window.
Is this investment advice?
No. Figures are for informational and educational use only. Past buybacks and dividends do not predict future returns.
Frequently asked questions
Does DaVita buy back its own stock?
Yes, DaVita (DVA) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does DaVita spend on share buybacks?
Trailing twelve months (TTM) buyback spend is about $1.65B (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is DaVita's buyback yield?
TTM buyback yield is about 15.91% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is DaVita's shareholder yield?
Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 15.91% combined (TTM-based where available).
Is DaVita diluting shareholders?
Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has DaVita's share count changed?
Diluted weighted average shares changed by about -28.2% over roughly five fiscal years (annual income statement data).
What is DaVita's buyback spend?
Latest reported buyback spend for DaVita (DVA) is $1.65B (period ending March 31, 2026).
How has DaVita buyback spend changed year-over-year?
DaVita (DVA) buyback spend changed +29.4% year-over-year on the latest annual filing.
What is the long-term growth rate of DaVita buyback spend?
DaVita (DVA) buyback spend compound annual growth rate is +4.2% over the most recent 5 years available.
When did DaVita buyback spend hit its highest annual value?
DaVita buyback spend reached its highest annual value of $2.38B in 2019.
What was DaVita buyback spend in 2024?
DaVita (DVA) buyback spend in 2024 was $1.39B.
What was DaVita buyback spend in 2025?
DaVita (DVA) buyback spend in 2025 was $1.79B.
Explore more
DVA Overview
Company profile, financial tools, and key metrics
DVA Revenue Counter
Earns $438.71 every second. See per minute, hour, and day.
DVA Earnings Counter
Earns $24.78 per second net profit. See per minute, hour, and day.
DVA Economic Scale
Exceeds West Bank and Gaza's GDP. Compare with world economies.
DVA What If Invested
What if you had invested $1,000? See historical returns from any date.
DVA How It Makes Money
Discover visual breakdown of $13.84B in revenue — where it comes from and where it goes.
DVA Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
DVA Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
DVA Daily Price Character
Balanced · 50.5% historical win rate (green days). Streaks & record days.
DVA Stock Split History
3 splits on record. Dates, ratios, and cumulative multiple.
DVA Financials
Revenue, EPS, EBITDA, market cap, debt and balance sheet history with annual and quarterly data.